MGTX Stock Overview
A clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MeiraGTx Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.88 |
| 52 Week High | US$7.60 |
| 52 Week Low | US$3.49 |
| Beta | 1.29 |
| 11 Month Change | -11.21% |
| 3 Month Change | -19.33% |
| 1 Year Change | -36.81% |
| 33 Year Change | -68.96% |
| 5 Year Change | -79.76% |
| Change since IPO | -74.13% |
Recent News & Updates
Recent updates
MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts
Jul 15MeiraGTx Holdings (NASDAQ:MGTX) Has Debt But No Earnings; Should You Worry?
Jun 19
MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met
Feb 15Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?
Sep 08Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)
Apr 11MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year
Mar 16MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be
Nov 16MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M
Aug 11MeiraGTx inks $100M debt agreement backed by manufacturing facilities
Aug 03MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans
Apr 29Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher
Mar 15MeiraGTx: Perceptive's Large Stake Makes It Interesting
Jan 19MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans
Dec 28Shareholder Returns
| MGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.7% | -4.0% | -4.4% |
| 1Y | -36.8% | 12.5% | 19.1% |
Return vs Industry: MGTX underperformed the US Biotechs industry which returned 12.5% over the past year.
Return vs Market: MGTX underperformed the US Market which returned 19.1% over the past year.
Price Volatility
| MGTX volatility | |
|---|---|
| MGTX Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MGTX's share price has been volatile over the past 3 months.
Volatility Over Time: MGTX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 387 | Alexandria Forbes | meiragtx.com |
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson’s program that has completed a Phase II trial.
MeiraGTx Holdings plc Fundamentals Summary
| MGTX fundamental statistics | |
|---|---|
| Market cap | US$300.31m |
| Earnings (TTM) | -US$93.14m |
| Revenue (TTM) | US$8.12m |
37.0x
P/S Ratio-3.2x
P/E RatioIs MGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGTX income statement (TTM) | |
|---|---|
| Revenue | US$8.12m |
| Cost of Revenue | US$0 |
| Gross Profit | US$8.12m |
| Other Expenses | US$101.27m |
| Earnings | -US$93.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,146.81% |
| Debt/Equity Ratio | 90.8% |
How did MGTX perform over the long term?
See historical performance and comparison